<DOC>
	<DOC>NCT00272688</DOC>
	<brief_summary>An open, observational health economic study to estimate marginal cost and health consequences of replacing conventional Parkinsons disease therapy with intraduodenal levodopa administered continuously</brief_summary>
	<brief_title>Continuous Delivery of Levodopa in Patients With Advanced Idiopathic Parkinsons Disease - Cost-benefit</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Clinical diagnosis of of idiopathic Parkinsons disease Motor fluctuations despite optimised per oral treatment Severe dementia, confusion, psychosis or depression Patients with contraindications against levodopa treatment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>